This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| No. | Item | No. | Item | No. | Item |
|---|---|---|---|---|---|
| A | Basic information | 1 | History | 2 | Causes |
| 3 | Genetics | 4 | General epidemiology | 5 | Pathophysiology |
| 6 | Symptoms | 7 | Signs | 8 | Screening |
| 9 | Diagnosis | 10 | Treatment | 11 | Prognosis |
| 12 | Prevention | 13 | References |
| A. ICD-10 code | D82.1 |
|---|---|
| B. Synonyms | DiGeorge syndrome; thymic lymphoplasia; aplasia or hypoplasia of thymus with immunodeficiency; pharyngeal pouch syndrome; 22q11.2 deletion syndrome; velocardiofacial syndrome (VCFS); conotruncal anomaly face syndrome (CAFS) |
| C. Special Copayment Reduction | V111 — 10% copayment rate applied for 5 years after rare disease registration |
The history of DiGeorge syndrome begins in the early 1960s with the American pediatrician and immunologist Angelo M. DiGeorge. In 1965, DiGeorge presented three neonates with severe hypocalcemia, congenital heart disease, and recurrent infections, and pointed out that their common anatomic abnormality was a defect in thymic development. At the time, the concept that the thymus is essential for immune development was just being established, and DiGeorge's report is regarded as the first clinical description of human T-cell immunodeficiency.
In 1968, Robert A. Good's group at the Cleveland Clinic reported that thymus transplantation could partially restore cellular immunity in this disease, a landmark experiment clinically proving that the thymus is the key organ for T-lymphocyte maturation. In the 1970s–1980s, the disease spectrum expanded greatly as detailed types of cardiac malformations (transposition of the great arteries, tetralogy of Fallot, interrupted aortic arch, etc.) were described together with cleft palate and facial dysmorphism.
From the late 1980s, as cytogenetics advanced, microdeletions of the proximal long arm of chromosome 22 began to be found in some patients. In 1992, Robert J. Shprintzen's group first reported that velocardiofacial syndrome (VCFS) shares the same genetic basis as DiGeorge syndrome, and in 1993 the mnemonic acronym CATCH22 (Cardiac defects, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia, 22q11) was proposed. With the clinical introduction of fluorescence in situ hybridization (FISH) in the mid-1990s, the 22q11.2 deletion was established as the most important molecular genetic basis of this group of disorders.
Since the 2000s, chromosomal microarray (CMA), with higher resolution than FISH, has become the standard diagnostic method, and genomic studies using next-generation sequencing (NGS) are revealing the functions of individual genes within the deleted region (TBX1, CRKL, DGCR8, etc.). Today, the umbrella term 22q11.2 deletion syndrome is used internationally, and DiGeorge syndrome is also used in a narrower sense to refer to the clinical phenotype in which immunodeficiency is prominent.
DiGeorge syndrome is mostly caused by a microdeletion at band 11.2 of the long arm of chromosome 22 (22q11.2). This deletion covers a region of about 3 Mb (megabases) and causes loss of more than about 40 protein-coding genes. Of these, the TBX1 gene is known to be the main determinant of the phenotype.
The 22q11.2 region is flanked by low-copy repeats (LCR22A–D), so non-allelic homologous recombination (NAHR) occurs frequently during meiosis. Deletion size ranges from about 1.5 Mb (smaller deletion) to 3 Mb (typical deletion), and the larger the deleted region, the more genes are affected. TBX1 is the most important single gene; mouse Tbx1 knockout models reproduced thymic, parathyroid, and cardiac malformations.
In a small number of patients, a 10p13-14 deletion (10p deletion) causes a similar phenotype. This location includes the GATA3 gene, which is involved in thymic and parathyroid development. In addition, very rarely, other chromosomal abnormalities such as 17p13 and 4q21 have been reported in association with a DiGeorge-like phenotype.
It has been confirmed that point mutations in the TBX1 gene can cause the DiGeorge phenotype alone, without a 22q11.2 deletion. In this case, the deletion is not detected on standard FISH testing, which can delay diagnosis.
Retinoic acid exposure in early pregnancy, maternal diabetes, alcohol consumption, and the like have been reported as acquired factors that disrupt pharyngeal pouch development and cause the DiGeorge phenotype. However, these account for a very small fraction of all patients, and the main cause is the genetic deletion.
The 22q11.2 deletion typically follows an autosomal dominant mode of inheritance. However, about 90% arise as sporadic (de novo) deletions, appearing newly without a prior family history. The remaining about 10% are inherited from one parent, who may show a mild phenotype or be an entirely asymptomatic carrier.
TBX1 (T-box transcription factor 1): Located at 22q11.21, it is the master regulator of pharyngeal arch/pouch development. It is essential for the development of the thymus, parathyroid glands, and aortic arch structures derived from the third and fourth pharyngeal pouches. Mice heterozygous for the deletion show thymic hypoplasia, parathyroid defects, and truncus arteriosus defects.
CRKL (CRK proto-oncogene like): Interacts with TBX1 and mediates signal transduction. CRKL knockout mice show malformations similar to TBX1 knockouts, and the phenotype is aggravated with compound heterozygous loss of both genes.
DGCR8 (DiGeorge syndrome critical region gene 8): Involved in microRNA biogenesis (cofactor of the Drosha complex). DGCR8 haploinsufficiency is presumed to affect neurodevelopment and cognitive function, contributing to 22q11.2-related neuropsychiatric phenotypes.
HIRA, UFD1L, CDC45L and others are also included in the deleted region and contribute to the pleiotropic phenotype.
The 22q11.2 deletion has nearly 100% penetrance, but expressivity varies greatly. Even within a family with the same deletion, one member may show severe immunodeficiency and complex heart disease while another has only mild learning disability. This variability is explained by regulation of the remaining normal allele, modifier genes, and environmental factors.
If one parent carries the 22q11.2 deletion, the risk of transmission to a child is 50%. For sporadic deletions, the recurrence risk is low, but the possibility of gonadal mosaicism cannot be excluded. Genetic counseling and parental chromosome testing must be performed.
22q11.2 deletion syndrome is known as the second most common chromosomal deletion syndrome after Down syndrome, occurring worldwide at a frequency of 1 per 2,000–4,000 births. This is much lower than Down syndrome at 1/68, but it is the most frequent in the category of single-gene deletions excluding trisomies.
There is no difference in frequency between the sexes; males and females are equally affected. No significant differences by race have been reported, and similar frequencies are observed in East Asian cohorts including China, Japan, and Korea. In Korea, according to Health Insurance Review & Assessment Service (HIRA) data, several dozen cases are registered for Special Copayment Reduction each year, and the actual prevalent population is estimated at several thousand or more.
Because of variable expressivity, diagnosis is often delayed. When cardiac malformations are severe, it may be diagnosed in the neonatal period, but when immunodeficiency is mild, recurrent infections may persist for years before diagnosis only after school age. There are also cases first diagnosed in adulthood when psychosis develops.
Congenital heart disease is present in about 75% of patients with the 22q11.2 deletion, thymic hypoplasia in about 75–80%, and hypocalcemia in about 50–60%. Palatal abnormalities (cleft palate or occult cleft palate) are reported in about 70%, and developmental delay and learning disabilities in almost all (>90%). The risk of developing schizophrenia spectrum disorder in adulthood is 20–30 times higher than in the general population, and the 22q11.2 deletion, as a single genetic risk factor for schizophrenia, accounts for about 1–2% of all patients with schizophrenia.
The pathophysiology of DiGeorge syndrome is due to failure of development of structures derived from the pharyngeal pouches, which takes place in weeks 4–6 of embryogenesis.
In vertebrate embryos, endodermal cells of the third and fourth pharyngeal pouches form the thymic epithelium and the primordia of the inferior and superior parathyroid glands, respectively. The ventral part of the third pharyngeal pouch forms the thymus and the dorsal part forms the inferior parathyroid glands (PIII), while the fourth pharyngeal pouch forms the superior parathyroid glands (PIV) and C cells (parafollicular cells around the thyroid). TBX1 regulates the migration and differentiation of this pharyngeal pouch endoderm and of the neighboring mesoderm-derived neural crest cells (NCC). When TBX1 is deficient, segmentation of the third and fourth pharyngeal pouches fails, and the thymus and parathyroid glands are not formed or are markedly hypoplastic.
Thymic epithelial cells coordinate the migration, selection, and maturation of T-cell precursors. When the thymus is completely absent (aplasia), T cells do not mature at all, presenting as complete DiGeorge syndrome, which shows a phenotype similar to severe combined immunodeficiency (SCID). When the thymus is hypoplastic (hypoplasia), T cells partially mature, resulting in partial DiGeorge syndrome with mild to severe cellular immunodeficiency. The complete form accounts for only about 1–2% of all patients.
Absence or dysfunction of the parathyroid glands reduces parathyroid hormone (PTH), which leads to decreased renal calcium reabsorption and reduced vitamin D activation. As a result, hypocalcemia and hyperphosphatemia occur, causing seizures and arrhythmias in the neonatal period.
Neural crest cells (NCC) near the third and fourth pharyngeal pouches are essential for remodeling of the aortic arch vessels and septation of the cardiac outflow tract. TBX1 is not directly expressed in neural crest cells, but supports NCC migration and differentiation in a non-cell-autonomous manner through the pharyngeal pouch endoderm. With TBX1 deficiency, NCC-inducing signals are lost, resulting in conotruncal malformations such as defective development of the fourth aortic arch, truncus arteriosus, and tetralogy of Fallot.
DGCR8 deficiency alone impairs dendritic development in the prefrontal cortex, and haploinsufficiency of SNAP29 (synaptic vesicle-related), SEPT5 (cell division), RANBP1 (RAN GTPase binding), and others affects synapse formation and information processing. This has been proposed as the reason the risk of schizophrenia is markedly increased in patients with the 22q11.2 deletion.
The clinical symptoms of DiGeorge syndrome are highly variable and are often summarized by the acronym CATCH22: Cardiac defects, Abnormal facies, Thymic hypoplasia, Cleft palate, Hypocalcemia, and chromosome 22.
Congenital heart disease is present in about 74–80% of patients. The most common types are tetralogy of Fallot (ToF), interrupted aortic arch (IAA type B), ventricular septal defect (VSD), persistent truncus arteriosus, and aortic arch anomalies (right aortic arch, aberrant subclavian artery). These conotruncal malformations occur most often in DiGeorge syndrome, and when such malformations are found, the 22q11.2 deletion must be considered.
Hypocalcemia due to hypoparathyroidism can present from the neonatal period. Symptoms include cyanosis, seizures, tetany, and QTc prolongation on ECG. Hypocalcemia can be aggravated by postoperative stress, infection, fever, and the like. In some cases, hypocalcemia first presents in childhood or adolescence.
Reduced T cells due to thymic hypoplasia present as recurrent infections. Patients are mainly vulnerable to viruses (CMV, EBV, RSV, etc.), fungi (Pneumocystis jirovecii, Candida, etc.), and opportunistic pathogens. In complete DiGeorge syndrome, life-threatening opportunistic infections occur from the neonatal period. In the partial form, otitis media, sinusitis, pneumonia, and the like recur and affect growth and development. Serious complications can occur after live vaccines (BCG, MMR, varicella, etc.).
Cleft palate (overt cleft palate), submucous cleft palate, bifid uvula, velopharyngeal insufficiency (VPI), and the like occur. VPI causes nasal regurgitation of food, hypernasality, and articulation disorders. Palatal abnormalities are reported in about 70% of all patients.
Developmental delay (language, motor, cognitive) is observed in almost all patients. Mean IQ is around 70–80, and performance IQ tends to be lower than verbal IQ. Attention-deficit/hyperactivity disorder (ADHD), autism spectrum disorder (ASD), and anxiety disorders are present. In adulthood, schizophrenia or schizoaffective disorder develops in about 25–30%, markedly higher than the general population risk (1%).
Signs of DiGeorge syndrome on physical examination and testing appear across multiple systems.
The characteristic facial features of DiGeorge syndrome are subtle and difficult to recognize except by experienced clinicians. Major findings include widely spaced eyes (hypertelorism), short palpebral fissures, ptosis, a low flat nasal bridge, small narrow nares (hypoplastic alae nasi), small auricles or preauricular tags, a short philtrum, a small mouth, and a small jaw (micrognathia/retrognathia). These findings vary greatly with age and race.
A murmur may be heard, but some malformations (particularly IAA) may have no murmur initially, so echocardiography is essential. Neonatal cyanosis and signs of congestive heart failure (tachypnea, hepatomegaly, feeding difficulty) may appear.
Peripheral blood tests show reduced T-lymphocyte counts. In particular, CD3⁺, CD4⁺, and CD8⁺ T-cell counts are all reduced, and the CD4/CD8 ratio varies. The proportion of naive T cells (CD45RA⁺) is markedly low. In the complete form, T cells are almost undetectable. Immunoglobulin levels are initially normal or elevated, and impaired antibody response capacity may appear later.
Chvostek sign (contraction of the corner of the mouth on tapping the facial nerve) and Trousseau sign (carpal spasm on inflation of a blood pressure cuff) may be positive. QTc prolongation and ventricular arrhythmias may be observed on ECG.
Characteristic findings are low serum calcium (total calcium <8 mg/dL, ionized calcium <1.1 mmol/L), elevated serum phosphate, low or inappropriately low PTH, and decreased 1,25-OH vitamin D (calcitriol). Thyroid function is mostly normal, but thyroid dysplasia may be present.
Absence of the thymic shadow may be seen on chest X-ray, but assessment may be difficult in the neonatal period. Chest CT confirms thymic hypoplasia or aplasia. Conotruncal malformations are diagnosed on echocardiography.
Neonatal screening for DiGeorge syndrome is not yet performed uniformly in all countries, but efforts to detect T-cell deficiency early are ongoing.
Measurement of T-cell receptor excision circles (TREC) is a method of indirectly quantifying naive T cells recently released from the thymus using neonatal dried blood spot samples. Low TREC values suggest reduced thymic function and can screen for SCID and DiGeorge syndrome (complete form). Since 2010, the United States has included TREC testing in newborn screening in all states, and in Korea it is performed at some institutions but is not yet mandatory nationwide. TREC testing is effective for complete DiGeorge syndrome, but false-negative results are possible in the partial form because T cells are partially present.
When congenital heart disease (particularly conotruncal malformations) is found on fetal ultrasound during pregnancy, the 22q11.2 deletion should be suspected. Cell-free fetal DNA (cffDNA) testing has begun to be applied to detection of the 22q11.2 deletion, but because of limitations in detection rate and false-positive rate, confirmatory testing is needed. Fetal chromosomal microarray via chorionic villus sampling (CVS) or amniocentesis is used for prenatal confirmation.
Testing for the 22q11.2 deletion is actively performed in all neonates and infants diagnosed with conotruncal heart malformations (IAA type B, truncus arteriosus, tetralogy of Fallot), cases with cleft palate and hypocalcemia, neonates with hypoparathyroidism, and neonates with absence of the thymic shadow. Testing of the parents and siblings of diagnosed patients is also considered.
In patients with suspected or diagnosed thymic hypoplasia, T-cell subset analysis (CD3, CD4, CD8, CD45RA, CD45RO), lymphocyte proliferation assays (stimulation with mitogens such as PHA), and immunoglobulin levels (IgG, IgA, IgM) are performed to assess the degree of immunodeficiency.
DiGeorge syndrome is confirmed by molecular genetic demonstration of a deletion in the 22q11.2 region. Clinical diagnosis alone is insufficient, and genetic testing is essential.
FISH (Fluorescence in situ hybridization) is the traditional standard method for diagnosing the 22q11.2 deletion, using a 22q11.2 probe to confirm the presence or absence of the deletion. Sensitivity is about 95% or higher for the typical 3 Mb deletion, but atypical small deletions (<1.5 Mb) may be missed. It is rapid, relatively inexpensive, and highly reliable in experienced laboratories.
CMA (Chromosomal microarray analysis) has higher resolution than FISH and can detect small and atypical deletions, while simultaneously analyzing genome-wide copy number variants (CNVs). It is currently recommended internationally as the first-tier confirmatory test for 22q11.2 deletion syndrome. It precisely defines the deletion boundaries, allowing the list of deleted genes to be identified, which is useful for prognostic prediction.
MLPA (Multiplex Ligation-dependent Probe Amplification) analyzes multiple probes within the 22q11.2 region simultaneously; it is more cost-effective than FISH and can quantitatively detect copy number abnormalities. It can detect not only deletions but also duplications.
Whole-genome sequencing (WGS) or whole-exome sequencing (WES) can detect the 22q11.2 deletion as a copy number variation and can simultaneously explore single-gene causes such as TBX1 point mutations. With falling costs and technological advances, they are increasingly used.
Immunologic evaluation must be performed in all patients with a confirmed 22q11.2 deletion. It includes peripheral blood lymphocyte subset analysis (CD3⁺, CD4⁺, CD8⁺, NK cells, B cells), proportions of naive T cells (CD45RA⁺CD4⁺) and memory T cells (CD45RO⁺), lymphocyte mitogen responses (PHA, ConA), serum immunoglobulins (IgG, IgA, IgM, IgE), and specific antibody titers (pneumococcus, tetanus, etc.). This distinguishes the complete and partial forms and determines the direction of treatment.
A multidisciplinary evaluation is needed, including echocardiography, ECG (QTc measurement), measurement of serum calcium, phosphate, PTH, and calcitriol, renal ultrasound (increased frequency of renal malformations), head and neck MRI (vascular anomalies), ophthalmologic examination, hearing tests, language and developmental assessment, and neuropsychological testing.
A multidisciplinary approach addressing the abnormalities of each system is key to treating DiGeorge syndrome, and the treatment strategy varies with the severity of immunodeficiency.
In complete DiGeorge syndrome (extremely reduced naive T-cell counts, loss of T-cell function), cultivated postnatal thymus tissue transplantation is the only curative treatment. The method was established by Louise Bregrio-Perry's group at Duke University Hospital in the United States and is performed before 6 months of age. When slices of thymus tissue from deceased donors are implanted into the patient's quadriceps muscle, the transplanted thymic epithelium attracts T-cell precursors and restores new T-cell production. When successful, T-cell counts gradually increase and a diverse T-cell repertoire is established. Long-term immune recovery is achieved in more than half.
In patients with the complete form for whom thymus transplantation is not possible or has failed, hematopoietic stem cell transplantation (HSCT) may be performed. However, without a thymus, transplanted T-cell precursors cannot mature into peripheral T cells, so the effect is limited, and complete immune recovery is difficult with HSCT alone. Some centers attempt a combined approach of thymus transplantation and HSCT.
In patients with the partial form, treatment intensity is determined according to the degree of immunodeficiency. When antibody production is impaired, immunoglobulin replacement therapy (IVIG/SCIG) is useful for preventing recurrent infections. Live vaccines (BCG, varicella, MMR, rotavirus, etc.) are contraindicated until T-cell function is confirmed. Prophylactic TMP-SMX is considered to prevent PCP (Pneumocystis pneumonia).
Conotruncal malformations require surgery in the neonatal and infant period. Hypocalcemia must be corrected before surgery, and when transfusion is needed, irradiated blood and CMV-negative blood are used to prevent GVHD (graft-versus-host disease). Tetralogy of Fallot, interrupted aortic arch, truncus arteriosus, and the like are operated on at centers experienced in pediatric cardiac surgery.
For acute hypocalcemia (seizures, tetany, arrhythmia), intravenous calcium (calcium gluconate) is given immediately. Chronic management combines oral calcium supplements and activated vitamin D (calcitriol). When some responsive PTH secretion remains, hypocalcemia may improve over time.
Early intervention programs such as speech therapy, occupational therapy, and physical therapy are essential. Special education support and learning assistance services are provided. Mental health monitoring continues in preparation for the risk of schizophrenia in adulthood, and when antipsychotic drugs are used, they are selected considering the risk of QTc prolongation.
Speech evaluation and surgical correction (pharyngeal flap surgery, etc.) are performed for cleft palate and VPI. When renal malformations are present, care is coordinated with a nephrologist. Regular dental, ophthalmologic, and otolaryngologic follow-up is needed.
The prognosis of DiGeorge syndrome varies greatly depending on the severity of cardiac malformations, the degree of immunodeficiency, and whether early treatment is given.
Congenital heart disease is the most important cause of death. With advances in modern pediatric cardiac surgery, most cardiac malformations are successfully corrected, and overall survival has improved greatly. When there are no cardiac malformations or they are successfully corrected, most patients survive into adulthood. Complete DiGeorge syndrome carries a high risk of death before age 2 from recurrent severe infections without thymus transplantation, but long-term survival is possible after successful thymus transplantation.
In patients with the partial form, T-cell counts tend to increase gradually during childhood, and some patients reach normal levels by adolescence. However, reduced T-cell repertoire diversity and functional abnormalities may persist. The risk of autoimmune diseases (autoimmune hemolytic anemia, ITP, thyroid autoimmunity, etc.) is increased, which is related to abnormal T-cell differentiation.
Developmental delay and learning disabilities tend to persist, but functional levels can be raised through early intervention. The risk of schizophrenia persists into adulthood, with onset concentrated in the 20s–30s. Early recognition of symptoms and prompt psychiatric treatment improve prognosis.
Because of abnormal T-cell regulatory function, autoimmune thrombocytopenic purpura (ITP), autoimmune thyroid disease (Hashimoto thyroiditis, Graves disease), arthritis, diabetes, and the like may occur. Regular monitoring for these is needed.
Because patients with the 22q11.2 deletion have multisystem problems throughout life, long-term follow-up by multiple specialties such as immunology, endocrinology, cardiology, psychiatry, and neuropsychology is essential. Even after reaching adulthood, a transition care system enabling a smooth transfer from pediatrics to adult specialties is important.
DiGeorge syndrome caused by the 22q11.2 deletion is fundamentally difficult to prevent, but the family's risk can be managed through genetic counseling and prenatal diagnosis.
For sporadic (de novo) deletions, the recurrence risk is low, but the possibility of gonadal mosaicism is explained. When one parent is a 22q11.2 deletion carrier, it is counseled that the deletion can be transmitted to 50% of children. Because a parent with a mild phenotype may remain undiagnosed, parental testing is recommended when a patient is diagnosed. Comprehensive counseling by a professional genetic counselor is needed before family planning.
In pregnancies of parents who carry the 22q11.2 deletion, fetal CMA or FISH testing is performed via chorionic villus sampling (CVS, 10–13 weeks of gestation) or amniocentesis (15–20 weeks of gestation). When conotruncal heart malformations are found on prenatal ultrasound, fetal genetic testing is recommended. When a 22q11.2 deletion is suspected on non-invasive prenatal testing (NIPT), invasive confirmatory testing must be performed.
In parents who carry the 22q11.2 deletion, preimplantation genetic testing (PGT-M or PGT-SR) of embryos after in vitro fertilization (IVF) allows selective transfer of embryos without the deletion. This is a suitable option for families who wish to avoid invasive testing during pregnancy.
Measures to prevent complications in diagnosed patients are important. Live vaccines are withheld until T-cell function has been assessed, to prevent disseminated infection. For transfusion, irradiated blood and CMV-negative blood components are used to prevent GVHD and CMV infection. Immunoglobulin replacement therapy is continued to prevent recurrent infections. To prevent hypocalcemic seizures, calcium and calcitriol are taken regularly, and dose increases are considered in stressful situations.
Early educational intervention and special education support for cognitive and developmental delay help patients build the greatest possible capacity for independent living. Patients and families are made aware of community mental health resources in preparation for mental health problems such as schizophrenia arising in adulthood.